D
Domain Therapeutics
Committed to improve patients’ life and to support physicians by delivering innovative immunotherapies to fight cancer
About Domain Therapeutics
Domain Therapeutics is a biopharmaceutical startup that is focused on developing innovative cancer treatments. The company's primary area of research is GPCR (G protein-coupled receptors) mediated-immunosuppression. In simpler terms, they are working on drugs that can help the immune system fight against tumors more effectively.
Read full description
The company's pipeline includes a variety of potential treatments, some of which are in Phase I of clinical trials. These include an A2aR/A2bR antagonist (M1069) and an EP4 receptor antagonist (DT-9081). They also have a couple of candidates in the discovery phase, including an anti-CCR8 antibody (DT-7012) and a PAR2 antagonist (DT-9045).
Domain Therapeutics operates in the biotech market, specifically in the oncology sector. Their business model revolves around the research, development, and eventual commercialization of their cancer treatments. They make money by progressing their treatments through the various phases of clinical trials, with the aim of eventually selling these treatments to healthcare providers and patients.
The company serves a broad range of clients, including healthcare providers, patients, and other stakeholders in the healthcare industry. They are committed to advancing multiple first-in-class and best-in-class programs to tackle GPCR-mediated immunosuppression in immune-oncology.
At a glance
- Status
- Operational
- Founded
- 2001
- Headquarters
- Illkirch, France
- Employees
- 36
- Open positions
- None listed
- Dealroom signal
- 62.9/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Spinout, Arts & Culture, Biotech and Pharma, radar de l'innovation, observatoire industrial tech, proteomics, DT and LS, observatoire healthtech
- Business model
- Manufacturing
- Investment activity
- 3 companies, latest Mar 2020
- Capital deployed
- $6.9M
- Preferred round
- ACQUISITION
Latest news
Press, funding announcements and product moves mentioning Domain Therapeutics.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANTOther financing | Jan 2024 | $11M | — | Undisclosed | ↗ |
| SERIES AOther financing | May 2022 | $42M | $168M | Turenne Capital · Seventure Partners · Omnes Capital · Schroders | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Domain Therapeutics is 3.6K monthly website visits, up 50% over the last three months. Domain Therapeutics's team declined 46.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Neurofit SASIllkirch, FranceOffers a wide range of neuroscience preclinical services including in vivo and in vitro validated tests
→
Prestwick ChemicalOrléans, FranceSmart chemical screening libraries, medicinal chemistry services
→
Ermium TherapeuticsParis, FranceDeveloping innovative therapies for auto-immune diseases, based on a breakthrough discovery
$26Mvaluation
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A13 investors entered at this stage
Sofinnova Partners
Auriga Partners
Bpifrance
Seventure Partners
CTI Life Sciences
3B Future Health Fund
Turenne Capital
Omnes Capital
Schroders
AdMare BioInnovations- VBViva BioInnovator
Panacea Venture
Seido Capital
Other known investors1 additional known investor
French National Centre for Scientific Research - CNRS
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Domain Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Domain Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.